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Background: The indication of implantable cardioverter defibrillator
(ICD) therapy for primary prevention of sudden cardiac death has been intro-
duced later in France than in other parts of the World. We aimed to assess the
risk-benefit ratio of this strategy over a 10 year period in France.
Methods: Multi-centric survey evaluating all patients implanted with an
ICD in the setting of primary prevention, from 2002 to 2012 in 12 centers.
Both benefit from ICD (first appropriate therapy, either anti-tachycardia
pacing or shock for each patient) and ICD-related morbidity (ICD-related
complications, including fatal events) during follow-up were assessed through
a median follow-up of 1000 days [470-1680].
Results: Of the 5,540 patients (overall 17,098 person-years) enrolled in the
survey, the implanted ICD devices were: 22.9% single-chamber, 23.6%
double-chamber and 53.5% CRT. Average age was 62.4±11 years (15.2%
female gender; 60.3% ischemic cardiopathy). During follow-up, the propor-
tion of patients with at least one appropriate therapy was 22.4% (median
occurrence time 435 days IQR 153-956). Per-procedural complications were
observed in 13.5%. Complications during follow-up occurred in 15.6% of pts
(including inappropriate shock in 6.7%). Death occurred in 832 patients
(15.2%), including 66 (7.9%) ICD-refractory sudden cardiac death and 14
(1.7%) ICD-related death. In addition, 3.2% of pts were transplanted. During
this same period of time, 708 patients (12.8%) underwent elective replacement
of the generator due to exhaustion and 164 (3.0%) were upgraded to CRT. On
Cox regression, advanced age, atrial fibrillation, ischemic cardiomyopathy,
higher NYHA class, low ejection fraction, per-procedural complications, and
appropriate therapies were independent predictors of mortality.
Conclusion: Our findings suggest that ICD therapy displayed a favorable
risk-benefit profile in this large cohort of primary prevention pts, with almost
one quarter of patients with at least one appropriate therapy, contra balancing
with 16% of significant complications (mainly inappropriate shocks) during
follow-up.
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